LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Corcept Therapeutics Inc

Затворен

СекторЗдравеопазване

71.47 0.29

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

70.59

Максимум

71.67

Ключови измерители

By Trading Economics

Приходи

-9.8M

21M

Продажби

-25M

157M

P/E

Средно за сектора

61.121

50.857

EPS

0.169

Марж на печалбата

13.069

Служители

500

EBITDA

-22M

3.4M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+95.19% upside

Дивиденти

By Dow Jones

Следващи печалби

28.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-194M

7.5B

Предишно отваряне

71.18

Предишно затваряне

71.47

Настроения в новините

By Acuity

38%

62%

129 / 381 Класиране в Healthcare

Corcept Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.06.2025 г., 18:52 ч. UTC

Печалби

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20.06.2025 г., 16:15 ч. UTC

Придобивния, сливания и поглъщания

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.06.2025 г., 20:13 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 20:11 ч. UTC

Пазарно говорене

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20.06.2025 г., 19:56 ч. UTC

Пазарно говорене

Crude Oil Slips to End Week -- Market Talk

20.06.2025 г., 18:35 ч. UTC

Пазарно говорене

Warehouse Clubs Seen Growing Market Share -- Market Talk

20.06.2025 г., 18:12 ч. UTC

Пазарно говорене

Gold Slides to Close Shortened Week -- Market Talk

20.06.2025 г., 17:56 ч. UTC

Пазарно говорене

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20.06.2025 г., 17:50 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 17:35 ч. UTC

Придобивния, сливания и поглъщания

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20.06.2025 г., 17:30 ч. UTC

Пазарно говорене
Печалби

Adobe's AI Headwinds Seen Fading -- Market Talk

20.06.2025 г., 17:03 ч. UTC

Печалби

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20.06.2025 г., 16:44 ч. UTC

Придобивния, сливания и поглъщания

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20.06.2025 г., 16:40 ч. UTC

Пазарно говорене
Печалби

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20.06.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.06.2025 г., 16:17 ч. UTC

Придобивния, сливания и поглъщания

UniCredit: ULI and UVA Are Expected to Merge in 2026

20.06.2025 г., 16:17 ч. UTC

Придобивния, сливания и поглъщания

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20.06.2025 г., 16:05 ч. UTC

Пазарно говорене

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20.06.2025 г., 15:56 ч. UTC

Пазарно говорене
Печалби

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20.06.2025 г., 15:26 ч. UTC

Пазарно говорене

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20.06.2025 г., 15:25 ч. UTC

Придобивния, сливания и поглъщания

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

20.06.2025 г., 15:25 ч. UTC

Придобивния, сливания и поглъщания

Competition Bureau Says Canadian Natural to Sell 75% Stake in Seiu Lake Natural Gas Plant to North 40 Resources

20.06.2025 г., 15:25 ч. UTC

Придобивния, сливания и поглъщания

Canada Antitrust Regulation Reaches Agreement With Canadian Natural Resources Over Proposed Buy of Schlumberger JV Interest

20.06.2025 г., 15:09 ч. UTC

Пазарно говорене

Canadian Retail Sales Show Reversal of Tariff Front-Running -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Corcept Therapeutics Inc Прогноза

Ценова цел

By TipRanks

95.19% нагоре

12-месечна прогноза

Среден 139.33 USD  95.19%

Висок 145 USD

Нисък 131 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Corcept Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Настроение

By Acuity

129 / 381 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.